Despite the ubiquity and complexity of atmospheric polycyclic aromatic compounds (PACs), many of these compounds are largely unknown and lack sufficient toxicity data for comprehensive risk assessments. In this study, nontarget screening assisted by in-house and self-developed spectra databases was, therefore, employed to identify PACs in atmospheric particulate matter collected from multiple outdoor settings. Additionally, absorption, distribution, metabolism, excretion, and toxicity properties were evaluated to indicate PAC's overall abilities to cause adverse outcomes and incorporated into a novel health risk assessment model to assess their inhalation risks.
View Article and Find Full Text PDFUnlabelled: Grip strength measurement, as a surrogate of sarcopenia diagnosis, effectively predicts secondary fracture risk in distal radius fracture patients. This simple tool enhances clinical practice by identifying high-risk patients for targeted interventions, potentially preventing or reversing functional decline and recurrent fractures.
Purpose: To evaluate grip strength and hand muscle cross-sectional area as predictors of secondary fracture risk in patients with a history of distal radius fracture (DRF), serving as surrogates of the diagnosis of sarcopenia.
Chloride is the most abundant anion in cells and plays many critical roles in maintaining cellular homeostasis. However, current chloride indicators are rare with inherent sensitivity in their emission properties, such as vulnerability to pH changes or short emission lifetimes. These limitations restrict their application in aqueous media and imaging.
View Article and Find Full Text PDFBackground: Temple hollowing is characterized by the reduction of volume in the temporal fossa, which can result in a skeletonized look and contribute to an aged appearance. This study aimed to evaluate the safety and effectiveness of the VYC-20L injectable gel for improvement of temple hollowing.
Methods: Adults with minimal, moderate, or severe temple hollows were randomized 2:1 to receive VYC-20L or no treatment.